Your browser doesn't support javascript.
loading
Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
Garrido, Manuel M; Marta, José C; Ribeiro, Ruy M; Pinheiro, Luís C; Holdenrieder, Stefan; Guimarães, João T.
Afiliação
  • Garrido MM; Department of Clinical Pathology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal; manuel.agarrido@chlc.minsaude.pt.
  • Marta JC; Department of Laboratory Medicine, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
  • Ribeiro RM; Department of Clinical Pathology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
  • Pinheiro LC; Biomathematics Laboratory, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
  • Holdenrieder S; Department of Urology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
  • Guimarães JT; Department of Urology, Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal.
In Vivo ; 35(6): 3431-3439, 2021.
Article em En | MEDLINE | ID: mdl-34697179
ABSTRACT
BACKGROUND/

AIM:

Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. PATIENTS AND

METHODS:

A total of 233 men who underwent prostate biopsy (PSA 2-10 ng/ml; Beckman Coulter Access® Hybritech® as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cobas® and the Abbott Architect® methods.

RESULTS:

Roche tPSA values were ≈1% higher than Beckman, while Abbott values were ≈5% lower. Roche had the highest diagnostic sensitivity (92%) compared to Beckman Coulter (87%) and Abbott (85%). Roche fPSA was ≈3% lower and Abbott ≈17% higher than that of Beckman. For the percentage of fPSA, Roche had the highest sensitivity (98%).

CONCLUSION:

Roche cobas® and Beckman Coulter Access® Hybritech® tPSA were almost interchangeable. While the agreement was acceptable for tPSA, this did not happen with fPSA and greater efforts for harmonization are required.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: In Vivo Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: In Vivo Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article